SE9902742D0 - New pharmaceutical formultion - Google Patents

New pharmaceutical formultion

Info

Publication number
SE9902742D0
SE9902742D0 SE9902742A SE9902742A SE9902742D0 SE 9902742 D0 SE9902742 D0 SE 9902742D0 SE 9902742 A SE9902742 A SE 9902742A SE 9902742 A SE9902742 A SE 9902742A SE 9902742 D0 SE9902742 D0 SE 9902742D0
Authority
SE
Sweden
Prior art keywords
formultion
new pharmaceutical
preparation
felodipine
solubilizer
Prior art date
Application number
SE9902742A
Other languages
English (en)
Inventor
Marianne Eklund
Jan-Erik Loefroth
Mats Sundgren
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9902742A priority Critical patent/SE9902742D0/sv
Publication of SE9902742D0 publication Critical patent/SE9902742D0/sv
Priority to KR1020007011312A priority patent/KR20010078703A/ko
Priority to CN99811100A priority patent/CN1319004A/zh
Priority to EP99964928A priority patent/EP1113786A1/en
Priority to JP2001510433A priority patent/JP2003504392A/ja
Priority to AU30956/00A priority patent/AU3095600A/en
Priority to PCT/SE1999/002474 priority patent/WO2001005376A1/en
Priority to CA002328102A priority patent/CA2328102A1/en
Priority to NO20004816A priority patent/NO20004816L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
SE9902742A 1999-07-20 1999-07-20 New pharmaceutical formultion SE9902742D0 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE9902742A SE9902742D0 (sv) 1999-07-20 1999-07-20 New pharmaceutical formultion
KR1020007011312A KR20010078703A (ko) 1999-07-20 1999-12-22 신규 제약 제제
CN99811100A CN1319004A (zh) 1999-07-20 1999-12-22 新的药用制剂
EP99964928A EP1113786A1 (en) 1999-07-20 1999-12-22 New pharmaceutical formulation
JP2001510433A JP2003504392A (ja) 1999-07-20 1999-12-22 新規医薬製剤
AU30956/00A AU3095600A (en) 1999-07-20 1999-12-22 New pharmaceutical formulation
PCT/SE1999/002474 WO2001005376A1 (en) 1999-07-20 1999-12-22 New pharmaceutical formulation
CA002328102A CA2328102A1 (en) 1999-07-20 1999-12-22 New pharmaceutical formulation
NO20004816A NO20004816L (no) 1999-07-20 2000-09-26 Ny farmasøytisk formulering

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9902742A SE9902742D0 (sv) 1999-07-20 1999-07-20 New pharmaceutical formultion

Publications (1)

Publication Number Publication Date
SE9902742D0 true SE9902742D0 (sv) 1999-07-20

Family

ID=20416534

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9902742A SE9902742D0 (sv) 1999-07-20 1999-07-20 New pharmaceutical formultion

Country Status (9)

Country Link
EP (1) EP1113786A1 (sv)
JP (1) JP2003504392A (sv)
KR (1) KR20010078703A (sv)
CN (1) CN1319004A (sv)
AU (1) AU3095600A (sv)
CA (1) CA2328102A1 (sv)
NO (1) NO20004816L (sv)
SE (1) SE9902742D0 (sv)
WO (1) WO2001005376A1 (sv)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211149A1 (en) * 2002-05-07 2003-11-13 Sherman Bernard Charles Extended release tablets comprising felodipine
GB0222612D0 (en) * 2002-09-30 2002-11-06 Univ Gent Controlled delivery system for bioactive substances
CA2585316C (en) * 2004-11-17 2013-06-25 Ares Trading S.A. Benzothiazole formulations and use thereof
CN101103964B (zh) * 2006-07-14 2010-09-29 海南盛科生命科学研究院 一种含有非洛地平的缓释制剂及其制备方法
KR100841877B1 (ko) * 2006-08-31 2008-06-27 조선대학교산학협력단 국소적으로 가용화 된 난용성 약물의 제어 방출형 제제조성물 및 그의 제조 방법
CN102784128B (zh) * 2012-07-31 2015-01-07 北京协和药厂 一种非洛地平缓释制剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
DE3738236A1 (de) * 1987-11-11 1989-05-24 Euro Celtique Sa Beisskapsel
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
DK0996429T3 (da) * 1997-10-27 2003-05-26 Merck Patent Gmbh Faste opløsninger og faste dispersioner i vand tungtopløselige lægemidler

Also Published As

Publication number Publication date
WO2001005376A1 (en) 2001-01-25
AU3095600A (en) 2001-02-05
EP1113786A1 (en) 2001-07-11
CN1319004A (zh) 2001-10-24
CA2328102A1 (en) 2001-01-20
NO20004816L (no) 2000-11-02
JP2003504392A (ja) 2003-02-04
NO20004816D0 (no) 2000-09-26
KR20010078703A (ko) 2001-08-21

Similar Documents

Publication Publication Date Title
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
DE69925133D1 (de) Pyrrolobenzodiazepine
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
ATE495154T1 (de) Pharmazeutische zusammensetzungen, die ccr5- antagonisierende piperazinderivate enthalten
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
SE9504661D0 (sv) New compounds
SE9904505D0 (sv) Novel compounds
SE9704545D0 (sv) Novel compounds
MXPA03001495A (es) Derivados de fenilalanina novedosos.
IL131651A0 (en) A pharmaceutical formulation containing benzimidazoles with amino acid/caclodextrin combinations and a process for producing the same
FI964583A0 (sv) Tokoferolkompositioner för distribution av biologiskt aktiva ämnen
ATE215954T1 (de) Pyrazolo(4,3-d)pyrimidin-derivate und diese enthaltende pharmazeutische zubereitungen
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
CY1111698T1 (el) Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
SE0102843L (sv) Stabiliserad oral farmaceutisk komposition innehållande jodid och jodat och metod
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
DE60019334D1 (de) Antivirale arznei
DE59907481D1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
TR200100895T2 (tr) Heterosiklik ikameli propanolamin türevleri, üretimi, ilaçları,kullanımı
IT1301968B1 (it) Derivati di eritromicina ad attivita' antibiotica
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.